Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography

Although Parkinson's disease with later dementia (PDD) and dementia with Lewy bodies (DLB) are pathologically characterized by the presence of intraneuronal Lewy inclusion bodies, amyloid deposition is also associated to varying degrees with both these disorders. Fibrillar amyloid load can now be quantitated in vivo with positron emission tomography (PET) using imaging biomarkers. Here the reported findings of 11C‐PIB PET studies concerning the amyloid load associated with PD and its influence on dementia are reviewed. It is concluded that the presence of amyloid acts to accelerate the dementia process in Lewy body disorders, though has little influence on its nature. Anti‐amyloid strategies could be a relevant approach for slowing dementia in a number of DLB and PDD cases. © 2009 Movement Disorder Society

[1]  J. Cummings,et al.  Intellectual Impairment in Parkinson's Disease: Clinical, Pathologic, and Biochemical Correlates , 1988, Journal of geriatric psychiatry and neurology.

[2]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[3]  J. Rinne,et al.  Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra , 1989, Annals of neurology.

[4]  A. Lees,et al.  A clinicopathologic study of 100 cases of Parkinson's disease. , 1993, Archives of neurology.

[5]  D. Mann,et al.  Amyloid beta protein (A beta) deposition in dementia with Lewy bodies: predominance of A beta 42(43) and paucity of A beta 40 compared with sporadic Alzheimer's disease. , 1998, Neuropathology and applied neurobiology.

[6]  Mann,et al.  Amyloid β protein (Aβ) deposition in dementia with Lewy bodies: predominance of Aβ42(43) and paucity of Aβ40 compared with sporadic Alzheimer’s disease , 1998 .

[7]  J. Growdon,et al.  Clinical and quantitative pathologic correlates of dementia with Lewy bodies , 1999, Neurology.

[8]  P. Lantos,et al.  Beta-Amyloid Deposition in the Temporal Lobe of Patients with Dementia with Lewy Bodies: Comparison with Non-Demented Cases and Alzheimer’s Disease , 2000, Dementia and Geriatric Cognitive Disorders.

[9]  G. Glosser,et al.  Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease , 2000, Neurology.

[10]  H. Ross,et al.  A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease , 2000, Neurology.

[11]  D. Dickson,et al.  Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease , 2000, Acta Neuropathologica.

[12]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[13]  D. Holtzman,et al.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Copeland,et al.  Progress towards testing the amyloid hypothesis: inhibitors of APP processing. , 2001, Current opinion in drug discovery & development.

[15]  Glenda M. Halliday,et al.  Cortical Lewy body pathology in the diagnosis of dementia , 2001, Acta Neuropathologica.

[16]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Joseph E Parisi,et al.  Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. , 2002, Archives of neurology.

[18]  F. Mastaglia,et al.  Prevalence of amyloid‐β deposition in the cerebral cortex in Parkinson's disease , 2003 .

[19]  William E. Klunk,et al.  The Binding of 2-(4′-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component , 2003, The Journal of Neuroscience.

[20]  F. Mastaglia,et al.  Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson's disease. , 2003, Movement disorders : official journal of the Movement Disorder Society.

[21]  K. Jellinger Prevalence of Alzheimer lesions in Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[22]  M. Emre Dementia associated with Parkinson's disease , 2003, The Lancet Neurology.

[23]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[24]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  S. DeKosky,et al.  Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  D. Aarsland,et al.  Neuropathology of dementia in Parkinson's disease: A prospective, community‐based study , 2005, Annals of neurology.

[27]  Lisa A. Weissfeld,et al.  Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease , 2006, NeuroImage.

[28]  M. Onofrj,et al.  Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.

[29]  E. Perry,et al.  Differences in neuropathologic characteristics across the Lewy body dementia spectrum , 2006, Neurology.

[30]  M. Viitanen,et al.  Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease , 2006, Neurology.

[31]  Keith A. Johnson,et al.  Imaging of amyloid burden and distribution in cerebral amyloid angiopathy , 2007, Annals of neurology.

[32]  Keith A. Johnson,et al.  Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. , 2007, Archives of neurology.

[33]  Majaz Moonis,et al.  Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees , 2007, The Journal of Neuroscience.

[34]  E. Tolosa,et al.  Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[35]  C. Rowe,et al.  In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies , 2007, The Journal of Neuroscience.

[36]  Matthias Reimold,et al.  [11C]PIB binding in Parkinson's disease dementia , 2008, NeuroImage.

[37]  A. Verma,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study , 2008 .

[38]  C. Rowe,et al.  Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[39]  Keith A. Johnson,et al.  Imaging amyloid deposition in Lewy body diseases , 2008, Neurology.